Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
WALTHAM, Mass., May 30, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
